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Background
Human bronchial epithelial cells produce a variety of
inflammatory mediators upon exposure to rhinovirus
(RV), a major precipitant of asthma exacerbations. We
hypothesized that anti-leukotriene (LT) treatment of
epithelial cells with or without exposure to supernatants
of RV-infected peripheral blood mononuclear cells
(PBMCs) may inhibit RV-induced up-regulation of
inflammatory cytokines.
Methods
PBMCs were isolated from a non-atopic, non-asthmatic
donor and exposed to 1MOI of RV-1B, and supernatants
were harvested at 48h post-infection. Subsequently,
BEAS-2B, a bronchial epithelial cell line, was infected
with RV, with or without conditioning with PBMC super-
natants. Treatment with anti-LT agents was performed
either on both PBMCs and BEAS-2B or at the bronchial
epithelial level only, with varying concentrations of mon-
telukast or MK-886. We evaluated the concentration of
inflammatory cytokines (IL-8, RANTES, IL-11, IL-6 and
IP-10) in culture supernatants at 48 hours after infection
of BEAS-2B cells with the use of commercially available
immunoassays.
Results
Treatment of PBMCs and BEAS-2B with montelukast at
concentrations of 10-4M to 10-6M, and with MK-886 at a
concentration of 10-4M significantly inhibited release of
IL-8 by RV-infected BEAS-2B. RANTES, IL-6 and IP-10
release was inhibited at all concentrations tested by both
drugs, while IL-11 release was inhibited only after
treatment with montelukast. Treatment of BEAS-2B cells
with montelukast or with MK-886 at a concentration
of 10-6M inhibited release of all cytokines measured,
irrespective of exposure to conditioned media of RV-
infected PBMCs, while 10-9M montelukast inhibited the
release of IL-8, IL-11 and IL-6, and 10-9M MK-886 sup-
pressed the release of IL-8 and RANTES.
Conclusion
Our results show that anti-LT treatment of RV-infected
bronchial epithelial cells, with or without exposure to con-
ditioned media of RV-infected PBMCs suppresses epithe-
lial RV-mediated inflammatory cytokine production. Our
observations may represent an indirect mode of action of
anti-leukotriene medication in virus-induced asthma.
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